What is diagnosis
superficial thrombophlebitis forearm linear ecchymosis
| Diagnosis | Supporting Features |
|---|---|
| Superficial thrombophlebitis (most likely) | Linear streak following venous course, puncture mark, hospital setting |
| Traumatic ecchymosis post IV/phlebotomy | Puncture site visible, linear tracking of extravasated blood |
| IV extravasation injury | Hospital setting, linear pattern from cannula site |
| Chemical phlebitis (from IV drugs/fluids) | Linear inflammation along vein, common post-infusion |
| Lymphangitis | Linear red streaking (though this appears more purpuric/ecchymotic than erythematous) |
Important disclaimer: This is a visual assessment only and does not replace clinical examination. A clinician should assess the patient directly, palpate for a cord-like vein, check for warmth/tenderness, and consider Doppler ultrasound if deep vein thrombosis cannot be excluded.
Search for recent clinical guidelines on IV-related thrombophlebitis management
\"thrombophlebitis\" AND \"peripheral intravenous catheter\" AND management
IV related thrombophlebitis clinical guidelines management 2023 2024 2025
PMID: 38593192
\"peripheral intravenous catheter\" phlebitis prevention treatment
PMID: 38142634
PMID: 35724261
https://www.safetyandquality.gov.au/clinical-care-standards/…
- Sabiston Textbook of Surgery, 21st ed., "Superficial Venous Thrombophlebitis"
| Intervention | Details |
|---|---|
| Remove the IV catheter | Immediate removal if still in situ |
| Warm compresses | Applied locally 3-4x daily to reduce inflammation |
| NSAIDs | Oral ibuprofen or topical diclofenac gel for pain/inflammation |
| Limb elevation | Reduces edema and discomfort |
| Compression | Compression stockings for lower limb SVT |
Recommendation 12a: For pediatric patients with SVT secondary to IV cannulation in the upper limb, the panel suggests NO anticoagulation rather than using anticoagulation. (Conditional recommendation; very low certainty evidence)
Recommendation 12b: For SVT not related to cannula (lower limb, cancer-associated, varicose veins), the panel suggests anticoagulation. (Conditional recommendation; very low certainty evidence)
- Sabiston Textbook of Surgery, "Superficial Venous Thrombophlebitis"
"No study has demonstrated clear benefit for systemic anticoagulation of brachial vein thrombosis. It is reasonable to treat these clots similarly to superficial thrombophlebitis of the leg."
- Rosen's Emergency Medicine, 10th ed., "Upper Extremity Venous Thromboses"
| Risk Factor | Recommendation |
|---|---|
| Hand dorsum cannulation | Avoid dorsal hand veins; use forearm |
| Reduced patient mobility | Encourage/promote mobility |
| Amoxicillin-clavulanate infusion | Monitor closely; consider central access |
| Omeprazole sodium IV | Monitor closely |
| Pain at site | Take pain complaints seriously - early predictor |
| Grade | Signs | Action |
|---|---|---|
| 0 | No symptoms | Observe |
| 1 | Slight pain/redness near IV site | Observe |
| 2 | Pain, erythema, swelling | Resite |
| 3 | Pain, erythema, swelling, palpable cord | Resite, document |
| 4 | Pain + cord >1 inch, purulent | Resite, treat infection |
| 5 | All above + fever | Treat as septic thrombophlebitis |
| Clinical Scenario | Recommendation | Source |
|---|---|---|
| IV cannula-related upper limb SVT | No anticoagulation; remove cannula, warm compress, NSAIDs | ASH/ISTH 2025 |
| Symptomatic SVT progression or PICC-related | Consider anticoagulation | ASH/ISTH 2025 |
| Lower limb SVT ≥5 cm GSV | Fondaparinux 2.5 mg/day x 6 weeks or rivaroxaban 10 mg/day x 45 days | Sabiston 2024 / SURPRISE trial |
| SVT within 3 cm of saphenofemoral junction | Anticoagulation (same as above) | Sabiston 2024 |
| Septic/suppurative thrombophlebitis | Antibiotics + surgical excision of vein | Consensus |
| PIVC site assessment | Minimum daily; remove immediately if phlebitis signs | ACSQHC Standard 2023 |
Disclaimer: These guidelines are for educational reference. Clinical decisions should integrate the individual patient's full clinical context, comorbidities, and a treating clinician's direct assessment.
AGE with s . dehydration
\"acute gastroenteritis\" AND dehydration AND management
| Feature | No Dehydration | Some Dehydration | Severe Dehydration |
|---|---|---|---|
| General condition | Well, alert | Restless, irritable | Lethargic / unconscious |
| Eyes | Normal | Sunken | Very sunken & dry |
| Tears | Present | Reduced | Absent |
| Mouth/tongue | Moist | Dry | Very dry |
| Thirst | Drinks normally | Drinks eagerly, thirsty | Drinks poorly / unable |
| Skin pinch | Returns immediately | Returns slowly (<2 sec) | Returns very slowly (>2 sec) |
| Fluid deficit | <5% | 5-10% | >10% |
| WHO Plan | Plan A | Plan B | Plan C |
- Rosen's Emergency Medicine, 10th ed., "Oral Rehydration Therapy"; Tintinalli's Emergency Medicine, 10th ed., "Treatment"
| Formula | Method |
|---|---|
| Mild (3-5%) | 30-50 mL/kg ORS over 4 hours |
| Moderate/Some (6-9%) | 60-80 mL/kg ORS over 4 hours |
| Replace ongoing losses | +10 mL/kg per stool; +2 mL/kg per vomit episode |
ORT is effective even if the patient continues to vomit - administer in small, frequent amounts (e.g., 5 mL every 1-2 min by spoon in infants).
- Rosen's Emergency Medicine, "Oral Rehydration Therapy"
"For patients with severe dehydration, isotonic intravenous fluids should be used, and lactated Ringer solution is the preferred commercially available option."
- Red Book 2021, "Vibrio cholerae"
Antiemetics reduce vomiting, ED length of stay, and admission need. - Tintinalli's EM
| Indication | Antibiotic |
|---|---|
| Infants <3 months with bloody diarrhea | Ampicillin + gentamicin or cefotaxime |
| Immunocompromised with severe illness | Empiric fluoroquinolone or azithromycin |
| Suspected Shigella (fever + bloody diarrhea) | Azithromycin 500 mg OD x 3 days |
| Travelers' diarrhea with fever | Ciprofloxacin 500 mg BD x 3-5 days OR azithromycin 500 mg OD x 3 days |
| Confirmed Campylobacter | Azithromycin (first line - due to fluoroquinolone resistance) |
| Confirmed Salmonella typhi | Azithromycin, ceftriaxone, or fluoroquinolone (per sensitivity) |
NEVER give antibiotics if STEC (O157:H7) is suspected - increases risk of Hemolytic Uremic Syndrome (HUS).
| Investigation | When Indicated |
|---|---|
| Electrolytes, BUN, Creatinine | Signs of systemic illness, severe dehydration, prolonged illness, very young/elderly |
| Blood glucose | Children (risk of hypoglycemia) |
| Stool culture / PCR multipanel | Bloody diarrhea, fever >38.5°C, >1 week illness, immunocompromised, traveler |
| CBC | Systemic symptoms, comorbidities |
| Stool ova & parasites | >2 weeks illness, travelers, immunocompromised |
| Urinalysis / urine SG | Assess hydration status |
Routine stool testing is NOT indicated for uncomplicated watery diarrhea. - Tintinalli's EM, 10th ed.
Clinical note: "Some dehydration" on WHO assessment mandates supervised Plan B ORT. Most patients respond well within 4 hours without IV fluids. The key is frequent reassessment and early escalation if ORT fails.
- Sources: Tintinalli's Emergency Medicine 10th ed.; Rosen's Emergency Medicine 10th ed.; Red Book 2021 (AAP); WHO IMCI guidelines
Rx
∆- AGaE with s.dehydration rx.
Rx
1. Tab. Ondansetron 4 mg
— 1 tab TDS (or SOS with vomiting)
— × 3 days
[Antiemetic — reduces vomiting, aids ORS intake]
2. Tab. Metronidazole 400 mg
— 1 tab TDS after food
— × 5 days
[For protozoal/anaerobic bacterial cause]
3. Tab. Racecadotril 100 mg
— 1 tab TDS before food
— × 3–5 days
[Antisecretory — reduces stool output without paralysing gut]
4. Tab. Domperidone 10 mg
(alternative antiemetic if Ondansetron unavailable)
— 1 tab TDS 30 min before meals
— × 3 days
5. ORS Sachet
— 1 sachet in 200 mL water
— Drink 200–400 mL after every loose stool
— Continue until diarrhea stops
6. Tab. Pantoprazole 40 mg
— 1 tab OD before breakfast
— × 5 days
[For gastric protection / associated nausea/dyspepsia]
IV Line — Insert 18G cannula
1. IV Ringer's Lactate (RL) 1 Litre
— Run at 500 mL/hour × 2 hours
— Then reassess hydration status
2. Inj. Ondansetron 4 mg IV / slow push
— TDS × 2–3 days (or until oral tolerated)
3. Inj. Pantoprazole 40 mg IV
— OD × 2 days
4. Oral rehydration to continue once vomiting controlled
| Drug | Reason |
|---|---|
| Loperamide | Avoid if fever or suspected dysentery |
| Antibiotics (empiric) | Most AGE is viral; not routinely needed |
| NSAIDs | Worsen GI mucosa |
| Codeine-containing antidiarrhoeals | Risk of paralytic ileus |
Note: This is a general adult prescription framework. Adjust doses for renal/hepatic impairment, pregnancy, or significant comorbidities. Metronidazole should only be continued if protozoal/anaerobic cause is suspected or confirmed.
∆- s anaemia
| Hb Level | Classification | Action |
|---|---|---|
| 10–12 g/dL (F) / 10–13 g/dL (M) | Mild | Oral iron + treat cause |
| 8–10 g/dL | Moderate | Oral iron ± IV iron |
| <8 g/dL | Severe | IV iron ± transfusion |
| <7 g/dL or symptomatic | Critical | Urgent blood transfusion |
EMERGENCY ORDERS
1. IV Access — 18G cannula (2 large-bore if actively bleeding)
2. Blood investigations STAT:
— CBC / FBC, Peripheral blood smear
— Serum Iron, TIBC, Ferritin (IDA workup)
— Serum B12, Folate levels
— Reticulocyte count
— LFT, RFT, Urine R/E
— Blood grouping & cross-match (2 units)
3. Packed Red Blood Cell (PRBC) Transfusion
— Indication: Hb <7 g/dL, OR Hb <8 with:
angina / cardiac compromise / severe dyspnoea /
hypotension / active bleeding / syncope
— Give: 1 unit PRBC over 3–4 hours
— Check Hb after each unit; target Hb 8–10 g/dL
— Pre-medicate: Inj. Chlorpheniramine 10 mg IV slow push
(to prevent transfusion reaction)
— Monitor: BP, pulse, SpO2, temperature every 30 min during
transfusion
Rx
1. Tab. Ferrous Sulphate 200 mg (65 mg elemental iron)
— 1 tab BD–TDS on empty stomach (or with food if GI upset)
— × 3–6 months (continue 3 months after Hb normalises
to replenish stores)
OR
Tab. Ferrous Fumarate 200 mg
— 1 tab BD
— × 3–6 months
2. Tab. Folic Acid 5 mg
— 1 tab OD
— × 3–6 months
[Co-deficiency common; enhances erythropoiesis]
3. Tab. Vitamin C (Ascorbic Acid) 500 mg
— 1 tab OD with iron tablet
— × 3 months
[Enhances non-haem iron absorption by ~30%]
4. Tab. Vitamin B12 (Cyanocobalamin) 500 mcg
— 1 tab OD
— × 3 months
[If B12 deficiency suspected / macrocytic component]
IV Iron Sucrose (Venofer)
— 200 mg in 100 mL NS over 30 minutes
— 2–3 infusions per week (total dose calculated by
Ganzoni formula or standard dosing)
— Maximum single dose: 200–300 mg
OR
Ferric Carboxymaltose (Ferinject)
— 500–1000 mg IV over 15 min (single infusion)
— Preferred in outpatient setting (fewer infusions needed)
Pre-medication before IV iron:
— Inj. Chlorpheniramine 10 mg IV slow push (prophylaxis)
— Test dose: give first 25 mg over 15 min, observe 15 min,
then give remainder if no reaction
| Cause | Treatment |
|---|---|
| Iron Deficiency (IDA) | Ferrous sulphate + treat source of blood loss |
| B12 / Folate deficiency | B12 + Folic acid supplementation |
| Hookworm / parasites | Tab. Albendazole 400 mg single dose |
| Malaria | Treat per malaria protocol |
| H. pylori (GI blood loss) | Triple therapy eradication |
| CKD / renal anaemia | EPO + IV iron |
| Menorrhagia | Gynaecological referral |
| GI bleed | GI workup, endoscopy |
| Timeline | What to Check |
|---|---|
| 7–10 days | Reticulocyte count (should rise = response confirmed) |
| 4–6 weeks | Repeat Hb / FBC (expect +1–2 g/dL rise) |
| 3 months | Hb should normalise |
| 6 months | Serum ferritin (stores replenished) |
Sources: Symptom to Diagnosis (4th ed.); Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine; WHO guidelines on anaemia management.